Arvinas Inc   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: New Haven CT United States (2013)

Organization Overview

First Clinical Trial
2019
NCT03888612
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Arvinas Androgen Receptor, Inc. | Arvinas Estrogen Receptor, Inc. | Arvinas Inc | Arvinas Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 16